Indeed, daily injection of XMU-MP-1 in estrogen-supplemented female NOD scid gamma (NSG) mice bearing MCF-7 xenografts over a 3-week period significantly inhibited tumor growth compared with vehicle treatment (Fig. 2f), suggesting that MST1/2 inhibition can reduce ER+ breast cancer growth in vivo. Here, ESR1 is linked to neoplasm.